Over the last few week’s we have been heartened to see that more and more states and healthcare providers are setting up programs that enable their citizens and customers that fall into vulnerable population groups to get early testing and confirmation of infection, and rapid treatment with monoclonal antibodies. We are working to set up a directory that will help proactive healthcare consumers to know what to do and where to go in their own state.
In the meantime, Lily’s ACTIV2 Clinical Trial for Bamlanivimab is also now running in virtually every state in the nation. This enables adults 18 and older to support critical additional testing and demonstration of the efficacy and safety of this antibody treatment for both:
- rapid treatment after infection to reduce the rate of severe disease, hospitalization or death; and
- prevention of infection entirely.
We encourage all citizens that want to help in the fight against COVID-19 to consider enrolling. However, we caution that individuals that are at high risk for adverse outcomes from COVID-19 – such as the elderly and those with pre-existing conditions – should consult with their physicians before considering this. Most likely, the trial itself will screen out such individuals, since this is a double-blind trial where a large proportion will get placebo rather than actual treatment.